RESUMEN
Nuclear hormone receptors (NHRs) are a family of proteins that function similarly as nuclear transcription factors. The NHR family includes glucocorticoid receptors, retinoic acid and retinoid receptors, vitamin D receptors, thyroxin receptors, and peroxisome proliferator activated receptors. These proteins are targets for some of the most commonly prescribed medications in dermatology, including corticosteroids, retinoids, and vitamin D analogues, all of which have limiting side effects. Advances in this field have led to better understanding of the mechanisms of NHR therapeutic and toxic effects, receptor subtypes, tissue distribution, and interaction with other molecules. New generations of more specific NHR ligands designed to increase therapeutic efficacy and limit adverse effects have dramatically expanded the clinical application of NHR-targeting drugs. The current understanding of NHRs and future directions for NHR ligands in dermatology are discussed.
Asunto(s)
Receptores Citoplasmáticos y Nucleares/efectos de los fármacos , Enfermedades de la Piel/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Colecalciferol/análogos & derivados , Colecalciferol/uso terapéutico , Dermatología/métodos , Dermatología/tendencias , Humanos , Retinoides/uso terapéutico , Factores de Transcripción/efectos de los fármacosRESUMEN
As the pathogenesis of psoriasis is better understood, specific targeted therapies are being developed. In addition to alefacept, etanercept, efaluzimab, and infliximab, discussed in separate articles in this issue, numerous other investigational therapies are currently in clinical trials, some of which will likely be approved in the future. We review the most promising of these therapies and their mechanisms of action.